12/12/2025
Last week in San Diego, the Acumen team attended the CTAD Conference where we presented posters detailing a nonclinical Enhanced Brain Delivery (EBD™) study focusing on fusing transferrin receptor binders to sabirnetug to facilitate its transport through the blood-brain barrier as well as recruitment strategies for our Phase 2 ALTITUDE-AD study of sabirnetug.
To see our posters visit: https://acumenpharm.com/publications/